knowledge -WSS

knowledge

author：fashion 2025-09-27 23:53:58 - browse：95762

President Joe Biden talks in the Roosevelt Room of the White House, in front of a painting of Theodore Roosevelt on a horse back — politics coverage from STAT — President Biden MANDEL NGAN/AFP via Getty Images

WASHINGTON — The White House is throwing its support behind a controversial authority that allows the government to undermine patent rights for certain high-priced medicines. It’s an early step that could have major ramifications for the American pharmaceutical industry, depending on whether and how federal officials actually use the authority.

The administration issued a framework for the National Institutes of Health to more broadly use so-called “march-in rights” — a policy that allows it to invalidate patent rights from drugmakers whose products rely on federally funded research. The framework lays out when the agency might assert this authority, and endorse using a drug’s price in that determination.

“We’ll make clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard told reporters. “These authorities are in existing laws, the last administration just didn’t want to allow them to be used in this way.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： CVS is on a mission to consolidate health care. Will it work?

focus

hotspot

WSS

Dog Aging Project founders on what lies ahead after losing funding

Surprise medical billing ban raises prices elsewhere

FDA endorses new sterilization method for medical devices

Maisha Meds is a PBM, but don't call it that

FDA endorses new sterilization method for medical devices

HPV vaccine, cervical cancer study delivers historic results

explore

knowledge

focus

Novavax promises a turnaround & Lilly roils the obesity market

Update the Apgar Score to remove skin color

United colonoscopy coverage change 'may cost lives,' doctors say

FDA endorses new sterilization method for medical devices

Trump demands the U.S. pay no more for drugs than other countries … again

To bolster infectious disease surveillance, genomics powerhouses team up

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Wildfire smoke exposes gaps in outdoor worker protections

Dog Aging Project founders on what lies ahead after losing funding

hotspot

What causes osteoarthritis? Researchers study link to brain protein

Surprise medical billing ban raises prices elsewhere

Immunocompromised patients offer clues on chronic Covid

New CMS data security rules will hurt Medicare, Medicaid research

What causes osteoarthritis? Researchers study link to brain protein

Medicare Advantage enrollment hits roughly 33.4 million

focus

focus

hotspot

focus